Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by Farallon Capital Management LLC

Farallon Capital Management LLC boosted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 53.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,279,227 shares of the medical equipment provider's stock after acquiring an additional 796,000 shares during the period. Farallon Capital Management LLC owned 3.29% of Lantheus worth $182,999,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UMB Bank n.a. grew its position in Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 247 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 208 shares during the period. Principal Securities Inc. purchased a new position in Lantheus during the fourth quarter worth about $28,000. Fidelis Capital Partners LLC acquired a new stake in Lantheus in the first quarter valued at about $34,000. Finally, FinTrust Capital Advisors LLC boosted its holdings in Lantheus by 53.6% in the 1st quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 232 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. JMP Securities cut their target price on Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a research note on Thursday, August 1st. Truist Financial reduced their target price on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research report on Thursday, July 25th. Leerink Partners increased their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Finally, Redburn Atlantic initiated coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.00.

Lantheus Price Performance

Shares of LNTH traded up $0.40 during trading hours on Tuesday, reaching $111.76. 600,461 shares of the company traded hands, compared to its average volume of 1,015,813. The stock has a market capitalization of $7.75 billion, a PE ratio of 17.00 and a beta of 0.50. The stock has a fifty day simple moving average of $105.27 and a 200 day simple moving average of $84.74. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. During the same quarter last year, the firm earned $1.40 earnings per share. The business's quarterly revenue was up 22.5% compared to the same quarter last year. As a group, research analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gary J. Pruden sold 12,530 shares of the company's stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the transaction, the director now directly owns 11,978 shares in the company, valued at $1,138,389.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Gary J. Pruden sold 12,530 shares of the business's stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares in the company, valued at $1,138,389.12. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Insiders have sold a total of 40,852 shares of company stock valued at $3,922,001 in the last quarter. 1.50% of the stock is currently owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.